Valuation: Tyra Biosciences, Inc.

Market Cap 1.83B 1.61B 1.5B 1.38B 2.58B 177B 2.63B 17.9B 6.98B 86.52B 6.88B 6.73B 300B P/E 2026 *
-11.9x
P/E 2027 * -10.8x
Enterprise Value 1.32B 1.16B 1.08B 992M 1.86B 128B 1.89B 12.9B 5.03B 62.36B 4.96B 4.85B 216B EV / Sales 2026 *
-
EV / Sales 2027 * 477x
Free-Float
97.14%
Yield 2026 *
-
Yield 2027 * -
1 day-1.28%
1 week-5.10%
Current month-4.54%
1 month+0.40%
3 months-18.89%
6 months+1.06%
Current year+15.98%
1 week 29.7
Extreme 29.7
33.05
1 month 29.26
Extreme 29.265
33.72
Current year 24.66
Extreme 24.66
40.65
1 year 9.96
Extreme 9.96
40.65
3 years 6.42
Extreme 6.42
40.65
5 years 4.93
Extreme 4.93
40.65
10 years 4.93
Extreme 4.93
40.65
Manager TitleAgeSince
Chief Operating Officer 51 2018-10-31
Chief Executive Officer 46 2018-10-31
Director of Finance/CFO 69 2022-12-31
Director TitleAgeSince
Chairman 58 2019-02-28
Director/Board Member 63 2025-01-28
Director/Board Member 56 2026-04-15
Date Insider Type Main position Quantity % Market Cap.
5/28/26 Free

Director

13,160 0.0221%
5/28/26 Free

Director

13,160 0.0221%
5/28/26
RA Capital Management LP
FreeCompany 13,160 0.0221%
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%-5.10%+182.84%+94.45% 1.83B
-1.92%-1.57%+48.70%+84.37% 55.92B
+0.93%+6.97%+62.83%+67.97% 56.67B
-2.20%-1.51%-21.36%-15.82% 23.28B
-0.87%-1.51%+3.05%+421.41% 23.28B
-0.36%-0.56%+36.00%-3.93% 20.54B
-1.34%+0.51%+25.02%-30.27% 17.78B
-1.44%-1.63%+37.07%+589.93% 15.9B
-1.30%-9.92%+160.67%+284.37% 14.64B
+0.03%-0.44%+24.30%+179.91% 13.99B
Average -0.98%+0.17%+55.91%+167.24% 24.38B
Weighted average by Cap. -0.83%+1.44%+43.72%+137.90%

Financials

2026 *2027 *
Net sales - 3.1M 2.73M 2.53M 2.33M 4.37M 300M 4.45M 30.29M 11.81M 146M 11.64M 11.39M 508M
Net income -166M -146M -135M -124M -233M -16.03B -237M -1.62B -631M -7.82B -621M -608M -27.12B -196M -172M -160M -147M -276M -18.96B -281M -1.91B -746M -9.25B -735M -719M -32.09B
Net Debt -511M -450M -418M -384M -721M -49.52B -734M -5B -1.95B -24.16B -1.92B -1.88B -83.8B -353M -311M -289M -265M -498M -34.2B -507M -3.45B -1.35B -16.68B -1.33B -1.3B -57.88B
Logo Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).
Employees
87
Date Price Change Volume
26-07-24 US$30.49 -1.01% 91,769
26-07-23 US$30.80 +0.69% 435,476
26-07-22 US$30.59 -3.96% 470,563
26-07-21 US$31.85 +2.56% 353,204
26-07-20 US$31.06 -3.35% 348,454
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
30.80USD
Average target price
51.97USD
Spread / Average Target
+68.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TYRA Stock